^
    Back
    Association details:
    Biomarker:FLT3 positive
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

    Published date:
    11/03/2022
    Excerpt:
    A retrospective study in adult pts with a newly diagnosed AML FLT3+ treated with intensive chemotherapy plus midostaurin...Fifty seven (78%) pts achieved first composite complete remission (CRc=CR+CRi) after 1 or 2 courses of induction…
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1182/blood-2022-170126